TNFRSF18 and neoplasm: GITR agonist increases activation, proliferation and effector function of CD8+ and CD4+ T cells [5–7], while decreasing intra-tumor regulatory T cells (Tregs) by depletion [8, 9] and Treg lineage stability alterations [10, 11], thus proving effective in various preclinical tumor models [7, 12, 13].